IDH889 is an Orally Available and Mutant Specific IDH1 Inhibitor
Heterozygous mutations in human cytoplasmic isocitrate dehydrogenase 1 (IDH1) at Arg132 (R132) occur in multiple cancer types, including acute myeloid leukemia, glioma, chondrosarcoma, and cholangiocarcinoma. In this study, Julian R. Levell, et al identified IDH889, which is a potent inhibitor of IDH1R132H by high throughput screening. Especially, IDH889 binds...
Olutasidenib is a Mutant IDH1 Inhibitor for the Treatment of AML or MDS
Acute myeloid leukemia (AML) is a kind of cancer diseases, a cancer of the myeloid line of blood cells. AML seriously affects patients’ life as we previously mentioned in our blog. Thus, it is necessary to find out more anti-acute myeloid leukemia agents. As we all konw, IDH (Isocitrate...